06.09.25 -- Clues To Mapping A Crisis-Ready Tech Transfer Playbook

Discover how scalable innovation is transforming viral vector production and driving broader, more equitable access to advanced gene therapies.

This article, the first in a two-part series, focuses on the initial stages of product development — specifically, how to move from candidate selection to a Phase 1 IND application.

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

By working with a single supplier that can handle the entire manufacturing value chain, companies can reduce risk, improve flexibility, and accelerate their time to market.

Unlike traditional drugs, AAV therapies require extensive characterization and testing, demanding varying degrees of analysis at each stage of development.

Quality agreements serve a critical role within a CDMO-Sponsor partnership. Review the importance of aligning objectives, quality standards, and compliance frameworks to establish a robust foundation.

Lonza has further improved its platform process with the creation of engineered plasmids that afford significantly higher titers and productivity levels compared to standard systems.

Learn how Aldevron's expertise helped to demonstrate reduced immune responses compared to using AAV serotype 9 for delivery.

Learn how a recent expansion into Western Pennsylvania is aiming to enable more biopharmaceutical firms to translate cutting-edge science and research into practical applications.